9M deaths caused by drug resistance
An estimated 9 million people per year die of cancer due to drug resistance acquired by tumors against the original drug targets.
Cancer-targeting immune cells loaded with oncolytic viruses
Bioeclipse is developing next generation immunotherapies which utilizes cancer-targeting immune cells loaded with oncolytic viruses, generating a multi-pronged attack on hard-to-treat tumors.
USD 53B market
In the initial basket trial, Bioeclipse Therapeutics is targeting a range of solid tumors with a combined global market size greater than $53 billion.
"CRX100 addresses a significant unmet medical need in fatal conditions for which there are limited treatment options. CRX100, which migrates to the tumor site, targets tumor cells and delivers the cancer-destroying virus, has the potential to significantly help those with chemotherapy-resistant or refractory solid tumors"
Oliver Dorigo M.D., PhD (Director of the Gynecologic Cancer Service at Stanford University)